NASDAQ:PHASPhaseBio Pharmaceuticals Stock Price, Forecast & News

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PHAS shares have increased by 48.6% and is now trading at $4.65. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.10. The company earned $0.32 million during the quarter, compared to the consensus estimate of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. View PhaseBio Pharmaceuticals' earnings history.

6 brokers have issued 1-year target prices for PhaseBio Pharmaceuticals' shares. Their forecasts range from $4.00 to $18.00. On average, they expect PhaseBio Pharmaceuticals' share price to reach $13.00 in the next year. This suggests a possible upside of 179.6% from the stock's current price. View analysts' price targets for PhaseBio Pharmaceuticals.

Media coverage about PHAS stock has been trending negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PhaseBio Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 2,250,000 shares, an increase of 13.6% from the June 15th total of 1,980,000 shares. Based on an average trading volume of 696,200 shares, the days-to-cover ratio is presently 3.2 days. Currently, 15.2% of the company's shares are short sold. View PhaseBio Pharmaceuticals' Current Options Chain.

Some companies that are related to PhaseBio Pharmaceuticals include Athersys (ATHX), Syros Pharmaceuticals (SYRS), Urogen Pharma (URGN), Catalyst Pharmaceuticals (CPRX), NextCure (NXTC), Clovis Oncology (CLVS), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), AC Immune (ACIU), BioSpecifics Technologies (BSTC), Satsuma Pharmaceuticals (STSA), Beyondspring (BYSI), Viking Therapeutics (VKTX), Emisphere Technologies (EMIS) and Flexion Therapeutics (FLXN). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), Amarin (AMRN), Viking Therapeutics (VKTX), VBI Vaccines (VBIV), TapImmune (MRKR), Selecta Biosciences (SELB), Zynerba Pharmaceuticals (ZYNE) and Dynavax Technologies (DVAX).

(PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PHAS stock can currently be purchased for approximately $4.65.

PhaseBio Pharmaceuticals has a market capitalization of $133.83 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at 610-981-6500 or via email at [email protected]